Sickle Cell Disease

New England CEPAC

ICER will assess the comparative clinical effectiveness and value of treatments for sickle cell disease:

  • Crizanlizumab (Novartis) is a P-selectin inhibitor, is currently under FDA priority review with an anticipated decision expected in the first half of 2020.
  • Voxelotor (Global Blood Therapeutics) is an HbS polymerization inhibitor, and Global Blood Therapeutics is planning to initiate and complete a rolling NDA for voxelotor before the end of 2019.

Date of review: March 2020

For questions, please contact Catherine Koola, Program Manager, at ckoola@icer-review.org.

Associated Meetings

March 26, 2020 10am-4pm ET

TBA

The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for sickle cell disease.


Key Dates

Associated Materials

08/30/2019

08/30/2019 – 09/20/2019

08/30/2019

09/30/2019

11/05/2019

11/21/2019
Model Analysis Plan

01/22/2020
Draft Evidence Report

01/22/2020
Draft Voting Questions

01/22/2020 – 02/19/2020
Public Comment

03/12/2020
Revised Voting Questions

03/12/2020
Evidence Report

03/12/2020
Response to Comments

03/26/2020
Meeting Agenda

03/26/2020
Evidence Presentation

04/16/2020
Final Evidence Report and Meeting Summary

04/16/2020
Report-at-a-Glance